Under the Spotlight of GLP-1, the Hidden Risks of Eli Lilly’s High Valuation Cannot Be Ignored Mar 26, 2026 Life Science
After Five Years of Sluggish Performance, Pfizer Finds Renewed Hope in High Dividends and Clinical Data Mar 25, 2026 Life Science
A Pullback or a Buying Opportunity? Analyzing Vertex Pharmaceuticals’ Growth Drivers for the Coming Year Mar 25, 2026 Life Science
Who Will Be the Next Oncology Giant? Axsome and Madrigal Could Overtake by 2026 Mar 25, 2026 Life Science
Tarsus Pharmaceuticals Chief Human Resources Officer Sells Shares, Transaction Highlights Company’s Commercial Momentum Mar 25, 2026 Life Science
Eli Lilly’s Weight-Loss Bet Comes With Risk. This ETF Offers a Smarter Alternative Mar 25, 2026 Life Science
April 10 Looms as Eli Lilly’s Next Big Test: Is the Stock a Buy Before the FDA Verdict? Mar 22, 2026 Life Science
Hims & Hers Joins Hands with Former Rival, Hidden Concerns Loom Over the Weight Loss Drug Market Landscape Mar 18, 2026 Life Science
How is Pfizer Tackling the “Blockbuster Drug Drought” in the Post-Pandemic Era? Mar 17, 2026 Life Science
Insider Cashes Out, Hedge Fund Piles In: The Two Faces of Olema After a 300% Rally Mar 16, 2026 Life Science
